Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vadadustat - Akebia Therapeutics

Drug Profile

Vadadustat - Akebia Therapeutics

Alternative Names: AKB-6548; MT 6548; PG 1016548; VAFSEO

Latest Information Update: 20 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Procter & Gamble
  • Developer Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation
  • Class Acetic acids; Amides; Antianaemics; Chlorobenzenes; Chlorophenols; Pyridines; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • Phase II Renal failure; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 19 Oct 2021 Akebia Therapeutics plans a phase III trial in Anaemia (In infants, In children, In adoescents) (PO, Tablet) in October 2021 (NCT05082571)
  • 05 Jun 2021 Updated efficacy data from the phase III PRO2TECT trials in Anaemia presented at the European Renal Association – European Dialysis and Transplant Association Virtual Congress (ERA-EDTA-2021)
  • 05 Jun 2021 Updated efficacy data from the phase III INNO2VATE trials in Anaemia presented at the European Renal Association – European Dialysis and Transplant Association Virtual Congress (ERA-EDTA-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top